Abstract
The distinction of CLL from other mature B-cell neoplasms, especially from leukemic forms of mantle cell lymphoma or splenic marginal zone lymphoma, can be difficult but has important prognostic and therapeutic implications. We measured CLLU1 (CLL upregulated gene1) mRNA by qPCR and found a highly significant difference between CLL and other lymphoid neoplasms (AUC 0.96, 95%CI 0.93-0.99). Based on our cut-off values we can predict CLL and other mature B-cell neoplasms with high probability (PPV 99% and 94%). Analysis of CLLU1 expression is a rapid and reliable tool that may facilitate the diagnosis of mature B-cell neoplasms especially in inconclusive cases.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / metabolism
-
Case-Control Studies
-
Cell Differentiation / genetics
-
Diagnosis, Differential
-
Gene Expression Regulation, Leukemic
-
Humans
-
Immunophenotyping
-
Leukemia, B-Cell / diagnosis*
-
Leukemia, B-Cell / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Lymphoma, B-Cell / diagnosis*
-
Lymphoma, B-Cell / genetics
-
Lymphoma, B-Cell / metabolism
-
Male
-
Middle Aged
-
Neoplasm Proteins / genetics*
-
Neoplasm Proteins / metabolism
-
RNA, Long Noncoding
-
Retrospective Studies
-
Up-Regulation / genetics
Substances
-
Biomarkers, Tumor
-
CLLU1 lncRNA, human
-
Neoplasm Proteins
-
RNA, Long Noncoding